Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Phase 2

Completed

Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7
Stage IIIA Gallbladder Cancer AJCC v7
Stage IVB Gallbladder Cancer AJCC v7
Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7
Unresectable Extrahepatic Bile Duct Carcinoma
Unresectable Gallbladder Carcinoma
Stage IVA Gallbladder Cancer AJCC v7
Stage IIIB Gallbladder Cancer AJCC v7
Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Nab-paclitaxel

First Posted Date: 2015-03-19

Last Posted Date: 2022-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT02392637

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Not Applicable

Withdrawn

Conditions: Malignant Neoplasm
Ototoxicity

Interventions: Drug: Dexamethasone
Other: Placebo
Drug: Cisplatin

First Posted Date: 2015-03-06

Last Posted Date: 2017-11-09

Lead Sponsor: Aaron Moberly

Registration Number: NCT02382068

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Phase 1

Active, not recruiting

Conditions: Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study

First Posted Date: 2015-03-06

Last Posted Date: 2024-10-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT02381535

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Yale University, New Haven, Connecticut, United States

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Phase 1

Completed

Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System
Carcinoma of Gallbladder
Bile Duct Cancer
Cholangiocarcinoma

Interventions: Drug: DKN-01
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2015-03-03

Last Posted Date: 2018-09-10

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 51

Registration Number: NCT02375880

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Phase 3

Active, not recruiting

Conditions: Germ Cell Tumor
Teratoma
Choriocarcinoma
Germinoma
Mixed Germ Cell Tumor
Yolk Sac Tumor
Childhood Teratoma
Malignant Germ Cell Neoplasm
Extragonadal Seminoma
Non-seminomatous Germ Cell Tumor

Interventions: Drug: paclitaxel
Drug: ifosfamide
Drug: cisplatin
Drug: pegylated G-CSF
Drug: G-CSF
Drug: carboplatin
Drug: etoposide phosphate
Procedure: stem cell reinfusion

First Posted Date: 2015-03-02

Last Posted Date: 2023-08-31

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 420

Registration Number: NCT02375204

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 122 locations

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: cisplatin
Drug: nimotuzumab
Drug: S-1

First Posted Date: 2015-02-25

Last Posted Date: 2015-02-25

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2

Registration Number: NCT02370849

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Procedure: Consolidative Surgery
Drug: Cisplatin

First Posted Date: 2015-02-19

Last Posted Date: 2024-02-20

Lead Sponsor: Jason R. Brown

Target Recruit Count: 83

Registration Number: NCT02365766

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Community Regional Cancer Care, Indianapolis, Indiana, United States
🇺🇸
IU Health Central Indiana Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery

Not Applicable

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Procedure: Group A adjuvant chemotherapy
Procedure: Group B adjuvant chemotherapy
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2015-02-19

Last Posted Date: 2015-02-19

Lead Sponsor: Campus Bio-Medico University

Target Recruit Count: 215

Registration Number: NCT02365935

Locations: 🇮🇹
campus bio-medico of Rome, Rome, Italy

Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2015-02-10

Last Posted Date: 2016-04-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT02360501

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Ramucirumab
Drug: Capecitabine
Drug: Cisplatin
Drug: S-1
Drug: Oxaliplatin

First Posted Date: 2015-02-09

Last Posted Date: 2018-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT02359058

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Ehime, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Osaka, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy